

21. (previously presented) A method of treating a subject having a condition selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections, said method comprising the step of administering to the subject a therapeutically effective amount of a compound according to claim 1.

22. (currently amended) The method of Claim 21 wherein said condition is caused by or contributed to by a bacterium is selected from the group consisting of *S. aureus*, *S. epidermidis*, *S. pneumoniae*, *S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae*.

23. (currently amended) The method of Claim 21 wherein said condition is caused by or contributed to by a bacterium that is a Gram-positive coccus.

24. (original) The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.


25 to 28. (canceled).

REMARKS

Receipt of the Office Action of December 7, 2004 is acknowledged. Claims 1, 3-18 and 21 have been allowed. Claim 2 has been amended to correct a typographical error. Claims 22 and 23 have been amended to provide proper antecedent basis for the word "bacterium."

Applicants respectfully submit that the amendments to Claims 2, 22 and 23 places all claims of the subject application in allowable form. Applicants therefore respectfully request issuance of a Notice of Allowance.

Respectfully submitted,

By: 
Thomas J. Dodd
Reg. No. 31010

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2782
Dated: February 7, 2005